Home » Novartis Strikes Licensing Deal With Incyte
Novartis Strikes Licensing Deal With Incyte
Swiss drugmaker Novartis has struck a licensing deal with Incyte Corp, paying $150 million
up front for access to therapies to treat patients with life-threatening blood disorders and cancers.
Forbes
Forbes
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May